Medicine & Life Sciences
Pharmacokinetics
100%
Neoplasms
50%
Maximum Tolerated Dose
38%
Child
35%
Irinotecan
32%
Vorinostat
24%
4-hydroxy-N-desmethyltamoxifen
23%
Temozolomide
23%
Topotecan
20%
Appointments and Schedules
19%
gemcitabine
18%
Pediatrics
18%
Carboplatin
17%
Neutropenia
14%
Glioma
14%
NSC 366140
13%
tanespimycin
13%
Neuroblastoma
13%
Area Under Curve
12%
Half-Life
12%
Leukemia
12%
veliparib
11%
Tamoxifen
11%
Pharmacology
11%
alvocidib
10%
anti-IGF-1R antibody A12
9%
Idarubicin
9%
Pharmaceutical Preparations
9%
Drug Therapy
9%
Therapeutics
9%
MLN 8237
9%
Central Nervous System Neoplasms
8%
Clinical Trials, Phase I
8%
Clinical Trials
8%
Bortezomib
8%
Cisplatin
8%
Thrombocytopenia
8%
Biological Availability
7%
Nausea
7%
Pemetrexed
7%
5-(3-methyl-1-triazeno)imidazole-4-carboxamide
7%
7-ethyl-10-hydroxycamptothecin glucuronide
7%
batracylin
7%
Cytochrome P-450 Enzyme System
7%
idarubicinol
7%
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione)
7%
Breast Neoplasms
7%
bizelesin
7%
Poly(ADP-ribose) Polymerase Inhibitors
6%
Bevacizumab
6%
Chemical Compounds
Pharmacokinetics
24%
Plasma
9%
Metabolite
7%
Dose
7%
Pemetrexed
6%
Dacarbazine
5%
Pyrrolobenzodiazepine
5%
Cyclophosphamide
5%
Gemcitabine
5%